Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904588 · ClinicalTrials.gov registry record · Phase 2
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
A Phase 2 study of Lymphoma and Myelodysplastic Syndromes, sponsored by Center for International Blood and Marrow Transplant Research.
- Active
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT04904588 is a Phase 2 study of Lymphoma and Myelodysplastic Syndromes that is active but no longer recruiting, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 300 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04904588, a Phase 2 study of Lymphoma and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Center for International Blood and Marrow Transplant Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Busulfan
- RADIATION Total-body irradiation
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California San Francisco - San Francisco
- Stanford University - Stanford
Florida
- University of Florida Health Shands Hospital - Gainesville
- University of Miami Sylvester Cancer Center - Miami
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Children's Healthcare of Atlanta - Atlanta
- Emory University Medical Center - Atlanta
Illinois
- Northwestern University - Chicago
- The University of Chicago - Chicago
Maryland
- University of Maryland Medical Center - Baltimore
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Tufts Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Medical Center - Mott Children's Hospita - Ann Arbor
- Karmanos Cancer Institute - Detroit
Colorado
- Colorado Blood Cancer Institute - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04904588
The ClinicalTrials.gov registry entry for NCT04904588 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (38% lower). The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04904588 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04904588 about?
NCT04904588 is a clinical study titled "HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide". This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamid...
What is the current status of trial NCT04904588?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2021-09-30. Estimated completion is 2026-12.
What conditions does trial NCT04904588 study?
This clinical trial studies the following conditions: Lymphoma, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT04904588?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Busulfan (DRUG), Total-body irradiation (RADIATION).
Who is sponsoring clinical trial NCT04904588?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04904588 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.